ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q40205866

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.

@en

type

Item

label

ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.

@en

prefLabel

ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.

@en

P1476

ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.

@en

P2093

Estefanía Pérez-López

http://www.w3.org/2001/XMLSchema#string

Jorge Labrador

http://www.w3.org/2001/XMLSchema#string

Lourdes Vázquez

http://www.w3.org/2001/XMLSchema#string

María Dolores Caballero

http://www.w3.org/2001/XMLSchema#string

María Victoria Mateos

http://www.w3.org/2001/XMLSchema#string

Mónica Cabrero-Calvo

http://www.w3.org/2001/XMLSchema#string

P2860

Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

ESHAP is an active regimen for relapsing Hodgkin's disease.

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Novel agents in Hodgkin lymphoma.

P304

1745-1753

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-014-2114-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ramón García-Sanz

P577

2014-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24863692

http://www.w3.org/2001/XMLSchema#string